![]() |
Name |
Methyl aeruginoate
|
Molecular Formula | C10H8N2O3S | |
IUPAC Name* |
methyl2-(3-hydroxypyridin-2-yl)-1,3-thiazole-4-carboxylate
|
|
SMILES |
COC(=O)c1csc(-c2ncccc2O)n1
|
|
InChI |
InChI=1S/C10H8N2O3S/c1-15-10(14)6-5-16-9(12-6)8-7(13)3-2-4-11-8/h2-5,13H,1H3
|
|
InChIKey |
UIRNTEPNRZQPMX-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 236.25 | ALogp: | 1.7 |
HBD: | 1 | HBA: | 6 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 72.3 | Aromatic Rings: | 2 |
Heavy Atoms: | 16 | QED Weighted: | 0.81 |
Caco-2 Permeability: | -4.877 | MDCK Permeability: | 0.00003620 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.019 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.474 |
Blood-Brain-Barrier Penetration (BBB): | 0.555 | Plasma Protein Binding (PPB): | 88.54% |
Volume Distribution (VD): | 0.459 | Fu: | 16.32% |
CYP1A2-inhibitor: | 0.984 | CYP1A2-substrate: | 0.653 |
CYP2C19-inhibitor: | 0.427 | CYP2C19-substrate: | 0.076 |
CYP2C9-inhibitor: | 0.319 | CYP2C9-substrate: | 0.776 |
CYP2D6-inhibitor: | 0.051 | CYP2D6-substrate: | 0.422 |
CYP3A4-inhibitor: | 0.098 | CYP3A4-substrate: | 0.166 |
Clearance (CL): | 6.954 | Half-life (T1/2): | 0.651 |
hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.215 |
Drug-inuced Liver Injury (DILI): | 0.973 | AMES Toxicity: | 0.033 |
Rat Oral Acute Toxicity: | 0.021 | Maximum Recommended Daily Dose: | 0.068 |
Skin Sensitization: | 0.062 | Carcinogencity: | 0.039 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.632 |
Respiratory Toxicity: | 0.957 |